DZ3389A1 - Traitement et prevention des etats associes de resistance cardiaque a l'insuline - Google Patents

Traitement et prevention des etats associes de resistance cardiaque a l'insuline

Info

Publication number
DZ3389A1
DZ3389A1 DZ003389A DZ003389A DZ3389A1 DZ 3389 A1 DZ3389 A1 DZ 3389A1 DZ 003389 A DZ003389 A DZ 003389A DZ 003389 A DZ003389 A DZ 003389A DZ 3389 A1 DZ3389 A1 DZ 3389A1
Authority
DZ
Algeria
Prior art keywords
prevention
treatment
insulin resistance
associated conditions
cardiac insulin
Prior art date
Application number
DZ003389A
Other languages
English (en)
French (fr)
Inventor
Ameet Nathwani
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of DZ3389A1 publication Critical patent/DZ3389A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DZ003389A 2000-06-16 2000-06-16 Traitement et prevention des etats associes de resistance cardiaque a l'insuline DZ3389A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2000/002347 WO2001095906A1 (en) 2000-06-16 2000-06-16 Treatment and prevention of cardiac insulin resistance associated conditions

Publications (1)

Publication Number Publication Date
DZ3389A1 true DZ3389A1 (fr) 2001-12-20

Family

ID=9884792

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ003389A DZ3389A1 (fr) 2000-06-16 2000-06-16 Traitement et prevention des etats associes de resistance cardiaque a l'insuline

Country Status (15)

Country Link
EP (1) EP1292301A1 (hu)
JP (1) JP2004503499A (hu)
CN (1) CN1592620A (hu)
AP (1) AP2002002688A0 (hu)
BG (1) BG107384A (hu)
BR (1) BR0017254A (hu)
CA (1) CA2436116A1 (hu)
DZ (1) DZ3389A1 (hu)
EA (1) EA200300028A1 (hu)
HU (1) HUP0301103A2 (hu)
IL (1) IL153452A0 (hu)
MX (1) MXPA02012619A (hu)
NO (1) NO20026000L (hu)
WO (1) WO2001095906A1 (hu)
YU (1) YU1203A (hu)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5902726A (en) * 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
EP0930882A2 (en) * 1996-08-02 1999-07-28 Institut Pasteur De Lille Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
WO1999059586A1 (en) * 1998-05-19 1999-11-25 Regents Of The University Of California Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis
MA26662A1 (fr) * 1998-07-21 2004-12-20 Smithkline Beecham Plc Derives de thiazolidinedione, compositions pharmaceutiques les contenant et leur utilisation

Also Published As

Publication number Publication date
EP1292301A1 (en) 2003-03-19
AP2002002688A0 (en) 2002-12-31
EA200300028A1 (ru) 2003-04-24
YU1203A (sh) 2006-05-25
CA2436116A1 (en) 2001-12-20
IL153452A0 (en) 2003-07-06
BG107384A (bg) 2003-09-30
WO2001095906A1 (en) 2001-12-20
MXPA02012619A (es) 2003-04-10
HUP0301103A2 (hu) 2003-08-28
BR0017254A (pt) 2004-01-06
NO20026000L (no) 2003-02-11
JP2004503499A (ja) 2004-02-05
CN1592620A (zh) 2005-03-09
NO20026000D0 (no) 2002-12-13

Similar Documents

Publication Publication Date Title
CY2018020I1 (el) Θεραπεια της νοσου ρομρε
SG93852A1 (en) Enhanced radiopacity of peripheral and central catheter tubing
DE69837474D1 (de) Antimikrobielle vorbeugung gegen und behandlung von aids und anderer infektiöser krankheiten
GB2368794B (en) Prevention and treatment of amyloidogenic disease
HUP0201205A3 (en) Prevention and treatment of amyloidogenic disease
ITRM980425A0 (it) Composizione ad attivita' neuroprotettiva per la prevenzione ed il trattamento delle alterazioni nervose e comportamentali legate a stati
FR2812197B1 (fr) Utilisation de co dans le traitement de l'inflammation des voies aeriennes superieures ou des bronches
ID27576A (id) Penggunaan siklosporin dalam pengobatan penyakit-penyakit peradangan autoimun
GB9912639D0 (en) Improvements in and relating to treatment of respiratory conditions
DZ3389A1 (fr) Traitement et prevention des etats associes de resistance cardiaque a l'insuline
EG22438A (en) Disposable pul-on garment having improved fitness to body
GB0407486D0 (en) Treatment and diagnosis of insulin resistant states
EG21720A (en) Elastic member and disposable garment having improved fitness to body during entire use
AU2003231279A8 (en) Prevention and treatment of type 2 diabetes
FR2774596B1 (fr) Utilisation de composes selenies dans la prevention et le traitement de la maladie d'alzheimer
MA25757A1 (fr) Traitement et prevention de conditions cardiaques associees a une resistance a l'insuline.
KR950022514U (ko) 무좀방지 및 발의 건강을 도모할 수 있도록 한 개량운동화
FR2797182B1 (fr) Orthese bivalve d'extension distale des doigts
PL360468A1 (en) Treatment and prevention of cardiac insulin resistance associated conditions
GB0030865D0 (en) Treatment and prevention of disease
GB0030866D0 (en) Treatment and prevention of disease
KR950022476U (ko) 발냄새 예방 및 무좀 예방대
KR950031945U (ko) 지압 및 무좀 예방 깔창
EP1152689A4 (en) METHOD FOR NONINVASIVELY DETERMINING THE NERVOUSITY OF ARRHYTMIAS IN PATIENTS
HK1037100A2 (en) A combination of genetic markers to indicate different types of diabetes in chinese to facilitate diagnosis and improve treatment